Malignant Neoplasm of Unknown Primary — Trials

Malignant Neoplasm of Unknown Primary — Trials · CancerIndex

Clinical trials

Registered studies

14,263 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4,163
Recruiting: 2,261
Ph III recruiting: 268
Growth YoY: +12.8%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,897)

clinicaltrialsPublishedShowing 751–800 of 14,263 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04069273	Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma(SEQUEL)	active not recruiting	Phase 2	58	Harry H YoonOTHER	1	Sep 3, 2026	clinicaltrials
NCT04246177	Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)	terminated	Phase 3	480	Merck Sharp & Dohme LLCINDUSTRY